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ABSTRACT
Type 2 diabetes is a progressive condition that
may require the combination of three oral
treatments to achieve optimal glycemic
management to prevent microvascular and
macrovascular complications whilst
minimizing the risk of acute complications
and side effects or adverse reactions to
treatments. With the widening availability of
treatment options and increasing importance of
individualized treatment pathways, including
personalized HbA1c targets, this article will
explore the mode of action of currently
available oral treatments, factors to consider
when individualizing HbA1c targets, the
relevance of estimated glomerular filtration
rate assessment, and the importance of
reviewing the clinical impact of all treatment
decisions.
Keywords: HbA1c targets; Oral hypoglycemic
agents; Type 2 diabetes
INTRODUCTION
Type 2 diabetes is a progressive life-long
condition that, if poorly managed, results in
significant morbidity as a result of micro- and
macrovascular complications [1, 2].
Macrovascular or cardiovascular disease is the
leading cause of mortality in individuals with
type 2 diabetes, accounting for 54% of deaths
[2]. Effective diabetes management to prevent
the development of long-term complications
requires intensive treatment of numerous risk
factors, including hypertension,
hypercholesterolemia, and hyperglycemia. In
recent years, the treatment options to achieve
optimum glycemic control have rapidly
expanded. There are currently five groups of
oral agents and two injectable therapies
available (Fig. 1). The challenge for clinicians
is determining which combination of treatment
is most appropriate for an individual with type
2 diabetes, with the recommendation being
that a maximum combination of three oral
treatments are used [3].
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PATHOPHYSIOLOGY
The number of people diagnosed with type 2
diabetes has escalated in the last decade, and is
reaching epidemic levels worldwide [4]. In
2014, the worldwide prevalence of diabetes for
20–79 year olds was 387 million, with type 2
diabetes accounting for 90% of cases [2]. This
rapid increase in the incidence of diabetes is
linked partly to the significant increase in the
worldwide population who are overweight or
obese. The latter account for 80–85% of those at
risk for developing type 2 diabetes [2], although
the aging populations of, in particular, many
westernized countries have also contributed to
its increased incidence.
The primary pathophysiological abnormality
in the majority of individuals that develop type
2 diabetes is insulin resistance. Insulin
resistance develops when the insulin receptor
on the surface of muscle and other cells change
shape. This results in an inability of the insulin
molecule to attach to the receptor opening the
glucose channel, which prevents the uptake of
glucose by the cells. Many ethnic groups have
underlying insulin resistance which is
significantly increased by any escalation in
weight. Type 2 diabetes is six times more
common in people of South Asian descent,
and three times more common in those of
African or African Caribbean origin [2].
As insulin resistance increases, the beta cells
compensate by producing additional insulin
which maintains blood glucose levels within
Fig. 1 Diabetes treatment tree. GLP1 glucagon-like peptide-1, SGLT2i sodium-glucose co-transporter-2 inhibitor, SU
sulfonylurea
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the normal range. However, with increasing
insulin resistance and progressive beta cell
failure, blood glucose levels become
increasingly difficult to maintain within the
normal range of 3.5–6.5 mmol/L. The high
demand for insulin and the glucose toxicity
that develops from increasing blood glucose
levels results in the development of beta cell
failure and a decline in insulin production.
Type 2 diabetes is preceded by a period of
impaired glucose regulation that can be
corrected if the body’s insulin requirements
are reduced by a reduction in weight, increase
in physical activity, or reduction in food intake,
or a combination of all three. Type 2 diabetes
develops when an individual’s demand for
insulin exceeds the amount they are able to
produce, even though at the time of diagnosis
they may have significant hyperinsulinemia.
Beta cell failure is also linked to increasing age,
and when type 2 diabetes develops in an elderly
person with a healthy body mass index (BMI)
the underlying cause is most likely beta cell
failure.
Insulin release occurs in two phases.
First-phase insulin release occurs 2–10 min
following a rise in blood glucose level; this
rapid release of insulin prevents the blood
glucose level from rising too high.
Second-phase insulin release is much more
controlled. The amount and speed of insulin
release is determined by the actual rise in blood
glucose level and the rate that carbohydrate is
digested. First-phase insulin release is
stimulated by the hormone glucagon-like
peptide-1 (GLP-1), which primes the beta cells
in the pancreas to release insulin in response to
a rise in the blood glucose level. GLP-1 is rapidly
destroyed in the body by the enzyme dipeptidyl
peptidase-4 (DPP4), and has a half-life of 2 min.
First-phase insulin release is absent in type 2
diabetes as a result of low levels of the GLP-1
hormone.
In a healthy individual, glucose should not
be present in the urine. As blood passes through
the kidney, all glucose passes through the
glomerulus into the nephric filtrate; 100% of
glucose, 99% of water, and other essential
electrolytes are reabsorbed through a process
of selective reabsorption as the filtrate passes
through the nephron. Glucose reabsorption
occurs predominantly (90%) in the proximal
tubule due to the action of the hormone
sodium-glucose co-transporter 2 (SGLT2),
which opens glucose channels in the wall of
the tubule. A normal renal threshold enables
10 mmol/L of glucose to be reabsorbed with
water reabsorption occurring through osmosis
in the loop of Henle. If blood glucose levels in
the filtrate exceed the renal threshold, glucose
will remain in the filtrate and result in reduced
water reabsorption and the presence of glucose
in the urine.
LITERATURE REVIEW
The publication of the UK Prospective Diabetes
Study (UKPDS) [5] brought into question the
importance of glycemic management in the
prevention of macrovascular complications in
type 2 diabetes. The impact of intensive
glycemic control on the prevention of
macrovascular disease, unlike in microvascular
disease, did not reach statistical significance.
The focus changed to intensive blood pressure
management. However, the publication of the
UKPDS follow-on study [1] demonstrated that
the impact of intensive glycemic control on
macrovascular complications does not become
evident as early as in microvascular
complications. Individuals who had
participated in the intensive glycemic control
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arms of the original UKPDS were noted to have
statistically better outcomes in relation to
myocardial infarction 10 years post
completion of the study than those who had
participated in the conventionally controlled
arm, even though for the subsequent 10 years
they had experience similar levels of control [1].
These findings have resulted in the
development of the term ‘‘metabolic memory.’’
This refers to the fact that good glycemic
control in the early years post diagnosis
protects against complications after
15–20 years of having type 2 diabetes, when
achieving good glycemic control is more
difficult due to declining insulin production as
a result of beta cell failure.
This current evidence has returned the focus
to optimum glycemic control in the
management of type 2 diabetes, balanced
against the potentially increased risk of
hypoglycemia. Hypoglycemia, especially in
individuals with existing macrovascular
disease, has been linked to an increase in
mortality [6].
Individualized HbA1c targets appropriate for
the individual’s age are actively encouraged
(Table 1) [3, 7], and are supported by the
development of treatment plans that utilize a
combination of treatments which take into
consideration age, occupation, and estimated
glomerular filtration rate (eGFR) to achieve
agreed individualized targets.
Treatment Options
Biguanides
Metformin is the only biguanide available, and
one of the oldest treatments for diabetes, dating
back to the 1960s. Metformin reduces
gluconeogenesis in the liver, lessening the
amount of glucose released by the liver,
particularly overnight. Additionally it increases
the sensitivity of muscle cells to insulin,
improving peripheral glucose uptake and
utilization. Due to its mode of action,
metformin rarely causes hypoglycemia.
The National Institute for Health
and Care Excellence [3] pathway for
blood-glucose-lowering therapy for type 2
diabetes recommends that metformin is
initiated as first-line therapy in asymptomatic
patients with a HbA1c greater than
48 mmol/mol, or higher than an agreed
individualized target despite changes to
lifestyle. Metformin should be commenced
with a starting dose of 500 mg once daily after
food with active titration over a 4-week period
to the maximum tolerated dose or maximum
dose of 2 g daily. Adopting this approach
reduces the common side effects of nausea,
vomiting, diarrhea, and abdominal pain.
Slow-release preparation of metformin could
be trialed if side effects mean that standard
release preparations cannot be tolerated.
If renal function declines below 45 mL/min/
1.73 m2 [8], a dose review should occur, with a
maximum dose of 1 g being prescribed.
Metformin should be discontinued in patients
whose eGFR is less than 30 mL/min/1.73 m2.
Due to an increased risk of lactic acidosis if a
sudden deterioration in renal function occurs,
metformin should be withheld prior to general
anesthesia, procedures requiring contrast
medium, and episodes of acute deterioration
in eGFR until the renal function normalizes.
Dehydration increases the risk of deterioration
in renal function; therefore, patients should be
aware that they should stop taking metformin if
they become unwell with diarrhea and
vomiting.
Sulfonylureas
Commonly prescribed sulfonylureas include
glimepiride and gliclazide; their mode of
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action requires a degree of beta-cell function, as
they stimulate the pancreas to increase insulin
secretion and as a result have a significant risk
of inducing hypoglycemia and can potentially
cause weight gain. NICE 2015 [3] recommends
their use as first-line therapy in symptomatic
patients, and should be titrated weekly whilst
osmotic symptoms are present based on blood
glucose self-monitoring results. Prescribing
sulfonylureas in the elderly population and in
people who drive requires caution because of
the associated risk of hypoglycemia.
Thiazolidinedione
Pioglitazone is the only thiazolidinedione
currently prescribable in Europe. It acts
directly at the cellular level, increasing the
sensitivity of the hepatic and muscle tissue to
endogenous insulin, and is particularly
efficacious in patients whose underlying
pathophysiology is insulin resistance. As
pioglitazone does not impact on insulin
secretion, the hypoglycemia risk is low unless
used in combination with a sulfonylurea or
insulin. Pioglitazone should be initiated at
15 mg, increasing to 30 mg after 3 months if
there has not been a response. Increasing to
45 mg would only be indicated if there was a
reduction in HbA1c with 30 mg but the target
HbA1c was not reached. If no additional
response is noted with 45 mg, the dose should
be reduced back to 30 mg [9]. If a 6 mmol/mol
Table 1 International Diabetes Federation HbA1c targets in the elderly (over 75 years old) [7]
Category Targets
Category 1: functionally
independent
Living independently
No impairment of ADLs
Receiving none or minimal care-giver support
HbA1c target: 53–59 mmol/mol
Category 2: functionally
dependent
Due to loss of function, having impairment of ADLs
Increased likelihood of requiring additional medical and/or social care
HbA1c target: 53–64 mmol/mol
Subcategory A: frail Combination of signiﬁcant fatigue, recent weight loss, severe restriction in mobility and
strength, increased propensity for falls, and increased risk of institutionalization
A recognized condition, and accounts for 25% of older people with diabetes
Clinical frailty scale or CSSHA 9-point scale (assessment tool)
HbA1c target: 60–70 mmol/mol
Subcategory B: dementia Degree of cognitive impairment leading to signiﬁcant memory problems, a degree of
disorientation or a change in personality, and unable to self-care
Mini cognitive tool (easy-to-use assessment tool)
HbA1c target: 60–70 mmol/mol
Category 3: end of life care Signiﬁcant illness or malignancy, and have life expectancy reduced to\1 year
Glycemic aim: hypo- and symptomatic hyperglycemia avoidance
ADL activity of daily living, CSHA Canadian Study of Health and Aging
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drop is not achieved after 6 months on 30 mg it
should be stopped. Due to an increased risk of
fluid retention, which could exacerbate or
precipitate heart failure, pioglitazone is
contraindicated in patients with or a history of
heart failure. Advice in relation to signs and
symptoms of heart failure such as edema should
be part of the patient consultation on initiating
treatment, and treatment should be stopped if
any symptoms develop. Liver function tests
should be carried out prior to initiation and
periodically thereafter due to a rare potential
risk of liver toxicity. If the alanine
aminotransferase (ALT) level remains more
than three times the upper limit of normal,
pioglitazone should be discontinued.
Suggestions have been made that pioglitazone
potentially increases the risk of bone fractures
and bladder cancer in a recent multi-population
pooled cumulative-exposure analysis; however,
it showed that there was no association with the
cumulative use of pioglitazone and the
associated incidence of bladder cancer [10].
Recent studies in individuals without diabetes
but with diagnosed insulin resistance and a
history of ischemic stroke or transient ischemic
attacks treated with pioglitazone showed a
significant reduction in the relative risk of
nonfatal heart attack or fatal and nonfatal
stroke, suggesting that addressing insulin
resistance though treatment with pioglitazone
could improve cardiovascular outcomes [19].
DDP4 Inhibitors, Commonly Known
as Gliptins
There are five different DPP4 inhibitors
currently on the market: alogliptin,
linagliptin, saxagliptin, sitagliptin, and
vildagliptin. They work by inhibiting DPP4,
which is an enzyme that destroys the hormone
GLP-1. GLP-1 aids glucose-dependent insulin
production, in particular first-phase insulin
release. Due to the glucose-dependent mode of
action, they are unlikely to cause hypoglycemia
unless used concomitantly with a sulfonylurea
or insulin. These groups of drugs are weight
neutral which, combined with the low risk of
hypoglycemia, means they are a
suitable treatment option for the elderly and
occupational drivers. If used as second-line
therapy with metformin, patients are not
required to undertake glucose self-monitoring
due to the low risk of hypoglycemia. DPP4
inhibitors have the associated increased risk of
pancreatitis and should be avoided in patients
with high triglycerides. Patients require
counseling on initiation about the signs and
symptoms of pancreatitis, with instructions for
when and how to seek urgent medical advice.
The majority of DPP4 inhibitors are taken once
daily and the doses need to be adjusted
according to renal function, with the
exception of linagliptin, which has no
restriction based on eGFR as it is excreted in
the bile. Post-surveillance trials have
highlighted that DPP4 inhibitors can cause
severe and disabling joint pain. It was found
that when DPP4 inhibitors were stopped, the
pain and symptoms resolved. Therefore, it
would be appropriate to consider a trial
without the DPP4 inhibitor if patients report
joint pains [11]. Concerns relating to DPP4
inhibitors and increased heart failure risk have
been raised in cardiovascular safety studies for a
number of treatments. The SAVOR-TIMI 53 trial
[12] found an increased risk of admission to
hospital for heart failure with saxagliptin. The
EXAMINE trial [13], which reviewed alogliptin,
and the TECOS trial [14], which reviewed
sitagliptin, did not identify any statistically
significant effect on hospital admissions for
heart failure. More recently, a further safety
review from the US Food and Drug
Administration [15] found that saxagliptin and
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alogliptin may increase the risk of heart failure,
especially in patients where heart failure or
kidney disease is already present. Patients
therefore should be warned of the signs and
symptoms of heart failure and advised to seek
urgent medical advice if concerned, and
healthcare professionals should contemplate
stopping the treatment if patients develop
heart failure. Applying these findings to
clinical practice would mean exercising
caution when utilized in patients with type 2
diabetes with heart and kidney disease, paying
particular attention to ensuring correct dosage
based on a current eGFR result. Response to
treatment initiation must be reviewed, and if
the HbA1c has not reduced by 6 mmol/mol
from when the treatment was initiated it should
be discontinued [3].
SGLT2 Inhibitors
These are the newest group of oral
hypoglycemic agents, and include
dapagliflozin, canagliflozin, and empagliflozin.
SGLT2 is a protein which encourages glucose
reabsorption in the proximal tubule in the
kidney. The SGLT2 inhibitors block the
receptor site, preventing activation of the
glucose channel and glucose reabsorption, so
the glucose remains in the renal filtrate and
ultimately the urine. As the filtrate passes
through the loop of Henle, water is reabsorbed
by osmosis, but as a result of the elevated levels
of glucose in the filtrate, reduced water
reabsorption occurs, resulting in increased
urine production. The loss of glucose in the
urine and thus calories can result in weight loss.
However, the side effects due to the glycosuria
include increased risk of urinary tract infections
and thrush/balanitis. For SGLT2 inhibitors to be
effective, good renal function is required, and
they should not be prescribed to patients whose
eGFR is less than 60 mL/min/1.73 m2. The
increased diuresis that can result from
glycosuria can potentially cause hypotension,
and SGLT2 inhibitors should be used with
caution in combination with a loop diuretic.
The three SGLT2 inhibitors vary in their
licensing guidance. Dapagliflozin is not
licensed with pioglitazone, is not
recommended in triple therapy, and should be
stopped if eGFR drops below 60 mL/min/
1.73 m2. Canagliflozin and empagliflozin are
both licensed for triple therapy and with
pioglitazone. They can be continued at the
lower prescribable dose even if eGFR drops
below 60 mL/min/1.73 m2 if a therapeutic
benefit has been noted, but are stopped if
eGFR drops below 45 mL/min/1.73 m2. SGLT2
inhibitors are taken once daily, with
canagliflozin and empagliflozin having the
option of a titrating dose. If the HbA1c has
not reduced by 6 mmol/mol following the
initiation of treatment, it should be
discontinued. Unless prescribed in
combination with a sulfonylurea or insulin,
then the risk of hypoglycemia is low.
As with all new diabetes oral therapies, they
require the study of cardiovascular endpoints to
assess safety. Empagliflozin, the most recent
SGLT2 inhibitor on the market, was found to
have added benefits of reducing the relative risk
of cardiovascular death, nonfatal heart attack,
or nonfatal stroke by 14% and a significant 38%
relative risk reduction in cardiovascular death
rate. These positive results come from the
EMPA-REG OUTCOME trial [16], but it still
needs to be determined if this relates to the class
of drugs, as cardiovascular outcome studies are
still in progress for canagliflozin and
dapagliflozin.
A number of clinical concerns have been
raised with this group of drugs. An increased
risk of acidosis with euglycemia has been noted,
particularly during the first 2 months of
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treatment [17]. Whilst the case numbers were
low and a third were identified as having type 1
diabetes, clear guidance has been issued that—
particularly when used in combination with
insulin or a sulfonylurea, where doses have been
reduced—vigilance for ketosis must be high.
Patients therefore should be informed of the
signs and symptoms of diabetic ketoacidosis
(DKA), and healthcare professionals still need to
consider DKA in patients who present with the
symptoms but whose glucose levels are within
the normal range and, as with metformin
treatment, should be suspended in patients
hospitalized for major surgical procedures or
acute medical illness and restarted once the
patient’s condition has stabilized.
Concerns in relation to an increased
frequency of fractures with canagliflozin
compared to placebo and links to reduced
bone mineral density have resulted in changes
to the drug label ‘‘warning and precaution’’ and
‘‘adverse reactions’’ [18]; further concerns have
been highlighted in the CANVAS study in
relation to increased amputation rates in those
patients with a high cardiovascular risk,
particularly those with a previous history of
amputation [20]. In clinical practice, this
requires healthcare professionals to be mindful
of patient risk factors before commencing this
treatment, and to consider if it actually the
most appropriate treatment choice for that
patient. Reporting side effects is an important
way of establishing any adverse impacts from
new drugs, and all healthcare professionals need
to be involved in this process when appropriate.
The importance of ensuring that patients
maintain good levels of hydration when
treated with SGLT2 inhibitors in order to
minimize the risk of potential adverse
outcomes is being increasingly being stressed
[20].
CASE STUDIES
The glycemic management of type 2 diabetes
requires clinicians to identify the most
therapeutic combinations of treatments, with
a maximum of three oral treatments being
prescribed. The choice of initial therapy is
usually clear, with metformin being identified
as first-line therapy in asymptomatic
individuals and those with eGFR[45 mL/min/
1.73 m2, and a sulfonylurea in symptomatic
patients.
The choice of second-line therapy is more
complicated, with factors such as weight,
hypoglycemic risk, occupation, and age to be
taken into consideration. Third-line treatment
would be required if HbA1c remains at
58 mmol/mol or greater, or above the agreed
target [3]. Figure 2 was developed by one of the
authors as a tool to facilitate treatment choices
for patients with type 2 diabetes in response to
local demands from healthcare professionals
who wanted more guidance in oral
hypoglycemic agents. Past experience has
shown that some clinicians swap one
treatment which was effective for another
treatment and the HbA1c then declines.
Figure 2 also indicates that HbA1c should be
monitored after a new treatment has been
First-line including target HbA1c
Second-line including target HbA1c
Third-line including target HbA1c
Type 2 diabetes due to?
Can’t have
Could use
Fig. 2 Preferred treatment plan
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initiated and that treatments which have not
had the therapeutic effect of a 6 mmol/mol
reduction in HbA1c should be discontinued.
With an estimated £10 billion annually spent
by the National Health Service on diabetes,
which equates to £1 million each hour [2], it is
imperative that treatments are discontinued if
they are not proving to be effective.
Case studies will be utilized in the following
section to help illustrate how appropriate
treatment decisions can be supported by
utilizing the clinical information for
individual patients and individualized HbA1c
targets. A rationale will then be provided for
each of the treatment decisions.
Case Study 1
An 81-year-old female, who lives alone,
mobilizes with a Zimmer frame, and has
vascular dementia. Recent blood results show
an eGFR of 49 mL/min/1.73 m2 and a HbA1c of
76 mmol/mol, and her BMI is 24 kg/m2. Current
treatment is metformin 1 g twice daily.
Treatment Recommendation
A DPP4 inhibitor. With an eGFR of 49 mL/min/
1.73 m2, alogliptin, saxagliptin, sitagliptin, and
vildagliptin could be used at a reduced dose.
Linagliptin would not need adjusting according
to eGFR as the dose is not affected by eGFR
results, so this could be used at the maximum
dose. The eGFR would need to be closely
monitored because the metformin dose would
need halving if the eGFR drops below 45 mL/
min/1.73 m2.
Table 2 shows the treatment decisions and
rationales for this patient.
Case Study 2
An unemployed 45-year-old white male. His
recent blood results show an eGFR[90 mL/
min/1.73 m2 and a HbA1c of 64 mmol/mol, and
his BMI is 36 kg/m2. He has had type 2 diabetes
for 4 years. Current treatment is metformin 1 g
twice daily and pioglitazone 45 mg.
Treatment Recommendation
An SGLT2 inhibitor. His eGFR is within the
normal range. His weight is his main concern.
Pioglitazone was shown to have a good
therapeutic effect at 30 mg, and his HbA1c
reduced by another 7 mmol/L when the dose
was increased to 45 mg, so pioglitazone would
be continued. Dapagliflozin is not licensed with
pioglitazone so it would not be appropriate in
Table 2 Treatment decision rationale for Case Study 1
Treatment options Decision Rationale
HbA1c target \70 mmol/mol IDF guidance, category 2, subcategory B: dementia
Glimepiride Unsuitable Increased risk of hypoglycemia
SGLT2i Contraindicated eGFR\60 mL/min/1.73 m2
Pioglitazone Unsuitable Unlikely to have a therapeutic effect with a BMI
of 24 kg/m2; increased fracture risk
DPP4i Suitable No risk of hypoglycemia
BMI body mass index, DPP4i dipeptidyl peptidase-4 inhibitor, eGFR estimated glomerular ﬁltration rate, IDF International
Diabetes Federation, SGLT2i sodium-glucose co-transporter-2 inhibitor
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this case, but empagliflozin and canagliflozin
would be an option for third-line therapy.
Table 3 shows the treatment decisions and
rationales for this patient.
Case Study 3
A 38-year-old male of Pakistani origin who
works as a taxi driver. Recent blood results
show an eGFR of 78 mL/min/1.73 m2 and a
HbA1c of 60 mmol/mol, and his BMI is 32 kg/
m2. He has had type 2 diabetes for 2 years.
Current treatment is metformin modified
release 2 g post main meal.
Treatment Recommendation
Pioglitazone 15 mg (titrated to 30 mg at
3 months if HbA1c remains above target) or
SGLT2 inhibitor. Insulin resistance is the
primary pathology of type 2 diabetes in this
patient due to his ethnic origin and raised BMI.
Pioglitazone has the potential to improve his
insulin sensitivity. A SGLT2 inhibitor will
potentially result in weight loss, and a 5–10%
weight loss would have a positive impact on
insulin sensitivity. As the patient is an
occupational driver with potentially erratic
meal patterns, it is important to minimize the
risk of hypoglycemia. Whichever treatment is
commenced first should be agreed upon
following discussion with the patient. The
unused treatment should be added if triple
therapy is indicated or the first choice is
stopped due to lack of impact on control or
side effects.
Table 4 shows the treatment decisions and
rationales for this patient.
Case Study 4
A 68-year-old female newly diagnosed with
diabetes from a random blood glucose level of
15.3 mmol/L (no urinary or blood ketones),
marked thirst, nocturia, and vulval thrush.
Blood results show an eGFR of [90 mL/min/
1.73 m2 and a HbA1c of 76 mmol/mol, and her
BMI is 22 kg/m2.
Treatment Recommendation
Glimepiride with blood glucose self-monitoring
to facilitate dose titration. A sulfonylurea will
have the quickest impact on symptoms, as it
will stimulate increased insulin production if
sufficient beta-cell function remains. Blood
glucose self-monitoring will be required to
facilitate rapid dose titration to correct high
blood glucose levels and in turn resolve
symptoms. If there is no response to
glimepiride in the first couple of weeks, rapid
referral to the specialist diabetes team for
insulin therapy is indicated. Metformin could
be added as second-line treatment if there is a
Table 3 Treatment decision rationale for Case Study 2
Treatment options Decision Rationale
HbA1c target 58 mmol/mol NICE 2015 (NG 28)
DPP4i An option May still have some beta-cell function but will not promote weight loss
Glimepiride An option May still have some beta-cell function; may increase weight
SGLT2i An option eGFR[60 mL/min/1.73 m2; encourages weight loss
DPP4i dipeptidyl peptidase-4 inhibitor, eGFR estimated glomerular ﬁltration rate, NICE National Institute for Health and
Care Excellence, SGLT2i sodium-glucose co-transporter-2 inhibitor
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positive response to glimepiride but the HbA1c
target is not achieved. Due to BMI, the
third-line treatment should be insulin.
Table 5 shows the treatment decisions and
rationales for this patient.
CONCLUSION
Prevention of the long-term complications of
type 2 diabetes is enhanced by optimum
glycemic control, especially in the early years
post diagnosis [1]. A maximum of three oral
treatments may be required due to the
progressive nature of type 2 diabetes. As more
treatment options become available, it is
essential that the correct treatments are used
for each individual. By obtaining a thorough
family, medical, and social history of the
individual with diabetes and treating the most
likely primary pathophysiology, in addition to
having a clear HbA1c target and assessing the
impact of all treatments commenced, good
glycemic control is possible in most
individuals with type 2 diabetes.
Table 4 Treatment decision rationale for Case Study 3
Treatment
options
Decision Rationale
HbA1c target \53 mmol/mol NICE 2015 (NG 28)
DPP4i An option but may not improve
control
Circulating insulin levels are likely to be high but ineffective
due to insulin resistance
Glimepiride Not an option as second-line
therapy
Risk of hypoglycemia; drives for a living; will not target insulin
resistance
Pioglitazone An option Will target Insulin resistance; no hypoglycemic risk
SGLT2i An option eGFR[ 60 mL/min/1.73 m2; encourages weight loss
DPP4i dipeptidyl peptidase-4 inhibitor, eGFR estimated glomerular ﬁltration rate, NICE National Institute for Health and
Care Excellence, SGLT2i sodium-glucose co-transporter-2 inhibitor
Table 5 Treatment decision rationale for Case Study 4
Treatment options Decision Rationale
HbA1c target \53 mmol/mol NICE 2015 (NG 28)
DPP4i Not an option May not be therapeutically potent enough to resolve symptoms or achieve
Hba1c target
Glimepiride An option Will have quickest impact on symptoms; NICE 2015 (NG 28)
Metformin An option NICE 2015 (NG 28)
Pioglitazone Not an option BMI\23 kg/m2; insulin resistance not the primary problem
SGLT2i Not an option Already symptomatic, may make symptoms worse
BMI body mass index, DPP4i dipeptidyl peptidase-4 inhibitor, NICE National Institute for Health and Care Excellence,
SGLT2i sodium-glucose co-transporter-2 inhibitor
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